Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pulmatrix Inc PULM

Healthcare
Pulmatrix, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat respiratory and other diseases with important unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders, such as... see more

Recent & Breaking News (NDAQ:PULM)

10 Biggest Mid-Day Losers For Wednesday

Benzinga.com  July 20, 2016

10 Biggest Mid-Day Gainers For Tuesday

Benzinga.com  July 19, 2016

Pulmatrix's New Life Sciences Animation Spotlights Inhaled Drug Delivery to Lungs

PR Newswire June 27, 2016

Pulmatrix Added to Russell Microcap Index

PR Newswire June 24, 2016

Pulmatrix Named "Stock of the Year 2016" by Konlin Letter

PR Newswire June 21, 2016

Pulmatrix's CEO Eyes $25 Billion COPD Market for Its Inhaled Drug Delivery Technology

Accesswire June 7, 2016

Pulmatrix Completes Dosing in Pilot Pharmacokinetic Evaluation of PUR0200 in Healthy Normal Volunteers

PR Newswire May 25, 2016

Pulmatrix Reports Q1 2016 Financial Results

PR Newswire May 5, 2016

New Global Energy, Inc. Launches Moringa Reserve, LLC

PR Newswire May 5, 2016

Pulmatrix's iSPERSE 'Inhaled' Drug Delivery Technology Offers Hope to Patients with Pulmonary Lung Disease

PR Newswire March 23, 2016

Pulmatrix To Present at 2016 Cowen and Company 36th Annual Healthcare Conference

PR Newswire March 4, 2016

Capsugel, Pulmatrix Enter Partnership To Develop, Manufacture Novel Inhaled Therapeutics

Press Releases February 16, 2016

UPDATE: Fairchild Semi Reiterates Co. Entered Merger Deal with ON Semi for $20/Share in Cash

Press Releases February 16, 2016

Capsugel and Pulmatrix Enter Collaboration to Develop and Manufacture Novel Inhaled Therapeutics

Press Releases February 16, 2016

Pulmatrix Initiates European Pilot Bioequivalence Study of PUR0200 for COPD

PR Newswire February 1, 2016

Pulmatrix to Present at Upcoming Investor Conferences

PR Newswire January 7, 2016

Pulmatrix, Inc. (Nasdaq: PULM) to Ring the Nasdaq Stock Market Opening Bell

GlobeNewswire December 22, 2015

Pulmatrix to List on Nasdaq Global Market

PR Newswire December 18, 2015

Stonegate Capital Partners Initiates Coverage on Pulmatrix, Inc.

Accesswire December 16, 2015

Pulmatrix Appoints Mark Iwicki Chairman of the Board

PR Newswire December 8, 2015